Routine measurement of natriuretic peptide to guide the diagnosis and management of chronic heart failure.

نویسندگان

  • James L Januzzi
  • Alan S Maisel
چکیده

Guide the Diagnosis and Management of Chronic Heart Failure To the Editor: We read with interest the viewpoint of Dr Milton Packer in a recent editorial1 accompanying a study examining the behavior of B-type natriuretic peptides in outpatients with congestive heart failure (CHF).2 Dr Packer1 suggested that B-type natriuretic peptides (BNPs) have not been shown to “improve upon the information derived from the patient-physician interaction” (p 2951). We disagree, citing data from the BNP (Breathing Not Properly) Multinational Study,3 in which the results of the results of BNP testing were superior to clinical judgment for the detection of CHF among patients presenting in an urgent fashion. Similar results are now pending for NT-proBNP. Dr Packer also asserted that no study has demonstrated that BNPs are superior to standard prognostic assessment in CHF. We would point out a recent study suggesting that N-terminal pro-BNP (NT-proBNP) results were superior to those of all methods for risk stratification among an outpatient heart failure population, even superior to the maximum oxygen uptake, which is the current gold standard for prognosticating outcomes in CHF.4 We also feel that Dr Packer’s1 characterization of BNP-guided therapy of outpatients with CHF as “an intellectual crutch to remind physicians to practice optimal medicine” (p 2952) is incorrect. We point out that the care of CHF patients is more often in the hands of non-cardiovascular specialists who may find biomarker-guided therapy useful to guide or ensure optimal therapy. Further, even when CHF patients are managed by a cardiovascular specialist, data suggest that there is room for improvement. We point out that Dr Packer’s comments are directly contradicted by the accompanying study,2 wherein only 57% of patients in a specialized CHF clinic were taking a -blocker, and no mention was made regarding the rates of treatment with spironolactone or biventricular pacing, presumably because of low rates of use. Lastly, we do not suggest that patients with low BNP or NT-proBNP levels should have therapies of proven benefit withheld or used in a suboptimal fashion. We enthusiastically agree with Dr Packer that we need to be excellent clinicians for our patients. We suggest, however, that in order to be excellent clinicians, we will need to continuously integrate our outstanding clinical skills with emerging tools that offer powerful diagnostic and prognostic information. As we learn more about BNP and NT-proBNP, we suggest that these markers will play an increasingly important role in the care of our patients with heart failure, without eroding the quality of care we deliver to these patients.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Evaluation of Serum Levels of N-terminal Pro Brain Natriuretic Peptide and Atrial Natriuretic Peptide in Neonates with Respiratory Distress

Background: Acute respiratory distress (ARD) is a critical respiratory failure due to lung injury of neonates leading to the clinical appearance of poor lung compliance. The aimed of the study was to evaluate the diagnostic values in differentiating respiratory from heart diseases with using of N-terminal pro brain natriuretic peptide (NT-pro BNP) and Atrial natriuretic peptide(ANP) in neonates...

متن کامل

Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure

For patients presenting with acute dyspnea, an incorrect diagnosis could increase the mortality risk. When used in the evaluation of patients with acute symptoms, brain natriuretic peptide and N-terminal pro-brain natriuretic peptide (BNP and NT-proBNP, respectively) testing is highly sensitive for the diagnosis or exclusion of acute or chronic decompensated heart failure (HF). It has been demo...

متن کامل

Natriuretic peptide guided heart failure management.

BNP or NT-proBNP testing has dramatically changed the management of acute heart failure patients by aiding in early recognition, prognostication and treatment. Furthermore, recent studies have shown that natriuretic peptide testing may guide the therapy of the stable chronic heart failure patients in out-patient setting. We will review the understanding of utilizing natriuretic peptide testing ...

متن کامل

Biomarkers Beyond the Natriuretic Peptides for Chronic Heart Failure: Galectin-3 and Soluble ST2

B-type natriuretic peptide (BNP) and NT-proBNP are widely used plasma biomarkers for the diagnosis of acute decompensated heart failure and prognosis for future cardiac disease. The clinical performance of these tests for management of chronic heart failure is somewhat limited by the markers' high biological variation. Biomarkers such as galectin-3 and soluble ST2 that reflect ongoing remodelin...

متن کامل

Evaluation of Brain Natriuretic Peptide plasma levels in children with Congenital Heart Diseases

ObjectiveThis study aimed to assess Brain Natriuretic Peptide in early diagnose of cardiac function in children with Congenital Heart Diseases.MethodologyThis study was performed on children with CHD and healthy. Severity of heart failure modified Ross classification system was used for grouping patients in four classes. For all participants, height, weight and head circumference were measured....

متن کامل

Clinical and Biochemical Assessments of Circulating B-Type Natriuretic Peptide as a Useful Marker in Pediatric Cardiac Patients

Background Although the left ventricle is the major site of BNP secretion in response to cardiac pressure or volume overload, the myocytes of both atria and ventricles secrete B- type natriuretic peptide (BNP). This study aimed to assess and compare the plasma levels of BNP in common pediatric cardiac diseases to clarify its pathophysiological role and evaluate its po...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Circulation

دوره 109 25  شماره 

صفحات  -

تاریخ انتشار 2004